Assessing the interoperability of single antigen bead assays across vendors to enhance the accuracy and efficiency of HLA antibody measurement in transplant patients.

Single Antigen Bead (SAB) assays are the cornerstone of HLA antibody detection in transplant immunology. However, discrepancies in mean/median fluorescence intensity (MFI) values between the two commercially available assays raise concerns about result interpretation and assay interoperability. Using 281 well-characterized serum samples positive for a broad range of HLA antibodies, we evaluated 118 core HLA antibody specificities for MFI concordance across platforms.

Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-Specific HLA Antibodies and C4d⁺ Antibody-Mediated Rejection in Kidney Transplant Recipients.

BACKGROUND Solid-phase assays to investigate the complement-activating capacity of HLA antibodies have been utilized to optimize organ allocation and improve transplant outcomes. The clinical utility of C1q/C3d-binding characteristics of de novo donor-specific anti-HLA antibodies (dnDSA) associated with C4d-positive antibody-mediated rejection (C4d⁺ AMR) in kidney transplants (KTx) has not been defined. MATERIAL AND METHODS Sera from 120 KTx recipients that had dnDSA concurrent with protocol/cause biopsy (median 3.

COVID-19 does not impact HLA antibody profile in a series of waitlisted renal transplant candidates.

HLA antibodies are typically produced after exposure to transplanted tissue, pregnancy, and blood products. Sensitization delays access to transplantation and preclude utilization of donor organs. Infections and vaccinations have also been reported to result in HLA antibody formation.